Navigation Links
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
Date:10/17/2007

ng on Day 1 of a 21-day cycle. The primary endpoint of this study is overall survival; the secondary endpoints include progression-free survival, overall response rate, duration of response and quality of life.

Pharmion has completed the Scientific Advice (SA) process with the European Medicines Agency (EMEA) and has reached Special Protocol Assessment (SPA) agreement with the US Food and Drug Administration (FDA) for the amrubicin Phase 3 SCLC study.

Interim findings from a Phase 2, multi-center clinical study of amrubicin in second-line sensitive SCLC patients provided encouraging initial results and informed the design of the pivotal study. These data were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in June 2007. Response data from 24 evaluable patients were analyzed, 15 treated with amrubicin and nine with topotecan. Of the 15 amrubicin-treated patients, 40 percent showed an objective tumor response, including two complete responses and four partial responses. All responses were confirmed. None of the nine topotecan patients showed a response to the drug. The median duration of progression free survival at the interim analysis was 4.1 months for amrubicin patients compared to 2.0 months for topotecan patients. Patients are being followed for overall survival. The major toxicity of amrubicin is myelosuppression, which is managed with standard supportive therapy and dose adjustments.

In addition to the Phase 2 study in second-line sensitive SCLC patients, Pharmion has two additional ongoing Phase 2 studies of amrubicin therapy for small cell lung cancer patients; one as single-agent therapy in patients refractory to first-line therapy; and one as single-agent or combination therapy with cisplatin versus cisplatin plus etoposide in previously untreated extensive stage patients.

"The Phase 2 studies in small cell lung cancer, in both sensitive and refractory patients, have thus far generated data f
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Malvern initiates European user group meetings for chemical imaging
4. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
7. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
10. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
11. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Colo. , Nov. 25, 2014   Heska Corporation ... "Heska" or the "Company"), a provider of advanced veterinary ... Robert Grieve , Executive Chair, will attend The Benchmark ... 2014. The one-on-one conference will be held at The Palmer ... from 8 a.m. to 2:30 p.m. Please email ...
(Date:11/26/2014)... , Nov. 25, 2014  Array ... today announced that its Chief Executive Officer, ... the following upcoming conferences.  The public is ... webcasts on the Array BioPharma website:  ... 3, 2014Time:1:30 p.m.  Eastern Time Location: Palace ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 ... AZN ) today announced that AMAGINE-2 TM , a ... in more than 1,800 patients with moderate-to-severe plaque psoriasis, met ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg given ... each shown to be superior to Stelara on the primary ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... SEOUL, South Korea, Dec. 5, 2011 /PRNewswire-Asia/ -- The ... Industry Development Institute announced that the Health Authority-Abu Dhabi ... National University Hospital, Asian Medical Center and Seoul St. ... a patient treatment-reference system in Abu Dhabi, on Nov. ...
... BEIJING, Dec. 5, 2011 /PRNewswire-Asia/ -- GC-Rise Pharmaceutical Co. ... holds a majority stake, was recently listed as one ... companies which rides on high growth over the past ... women,s health in China, saw its operating revenues rising ...
Cached Medicine Technology:South Korea Signs Accord with Abu Dhabi Health Authority on Hospital Service Agreement 2Women Health Expert GC-Rise Listed in Deloitte's 50 Top-performing Companies 2
(Date:11/27/2014)... By Randy Dotinga ... -- Some people,s brains seem pre-wired to acquire a second ... beyond their mother tongue will likely gain a brain boost, ... connected and integrated after learning," said study co-author Ping Li, ... Pennsylvania State University. But it,s even more interesting, Li said, ...
(Date:11/27/2014)... November 27, 2014 In order to enable ... Sharpes, Fla., designed an easy way to avoid touching a ... He then created a prototype of the patent-pending Toilet Tamer, ... a toilet seat and/or lid in a more sanitary manner. ... spread of germs. Overall, it promotes good hygiene and peace ...
(Date:11/27/2014)... November 27, 2014 Tylenol lawsuits ( ... allegedly injured by the medication are continuing to move ... is looking ahead to a status conference in December, ... Scheduling Order issued earlier this year, a conference in ... at 10:00 a.m. Items likely to be discussed at ...
(Date:11/27/2014)... “LAB.C” was featured on NewsWatch as part ... coolest technology products available to consumers. Mallory Sofastaii, a technology ... and shared with viewers the company offers a cable ... , Consumers love portability and functionality. A unique mobile ... the iPhone5 and 5S has a portable USB charger built ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 HealthPostures, ... office ergonomics equipment , has announced that it ... Commercial Office Environments. The partnership will put HealthPostures' ... furnishings location. , In addition to having its ... dealer partnership promotes HealthPostures' products with the business ...
Breaking Medicine News(10 mins):Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
... the number of seats in existing facilities to fill the ... the central government's proposed quota policy, says Chief Minister Arjun ... medical institutions and open more institutes in the state," said ... doctors and this was the only to "adjust the numbers". ...
... mosquito-transmitted viral fever, has claimed 12 lives in Betul district ... more districts//. ,'With three more deaths Sunday - two ... number of deaths allegedly due to Chikangunya fever in Betul ... here said Thursday. ,'The dead include a 10-year-old ...
... peripheral artery disease (PAD) patients have showed lesser death ... ,Researchers have also indicated that less physically active ... ,‘We found that there is a survival ... active in their daily routines,’ said Mary M. McDermott, ...
... can cause developmental delays in infants whose mothers were ... banned in the United States, officials in Africa plan ... malaria. ,According to study author Brenda Eskenazi, a ... the University of California, Berkeley, the potential benefits of ...
... that vaccines that contain mercury do not increase ... scientists examined patterns between the developmental disorder and ... in the journal Pediatrics. ,Their research ... children given shots after thimerosal, a mercury-based preservative, ...
... the All India Institute of Medical Sciences remained crippled ... to protest the move to sack its Director P ... were closed since last evening as resident doctors and ... apex body headed by Union Health Minister A Ramadoss ...
Cached Medicine News:Health News:Chikungunya Death Toll Raises to 12 in Madhya Pradesh 2Health News:Physical Activity benefited Peripheral Artery Disease (PAD) patients 2Health News:Developmental Delays in Infants Linked to DDT 2
... This stool is unquestionably the finest operating ... especially for the ophthalmic surgeon who must ... A poor stool can unexpectedly shift resulting in ... solid base of five sturdy casters. A "foot ...
This is a 2.5x focusing Galilean telescope with a range from 70cm to infinity. Ideal for use at sporting events, as well as for a wide range of hobbies....
This 6x or 8x aspheric magnifier is fitted with a distance piece and is particularly useful for patients with tremor or focusing difficulties. The magnifier can be either spectacle mounted or hand h...
All Keeler magnifiers and telescope are available on a clip to fit over the patient's own spectacle...
Medicine Products: